Search

Your search keyword '"Röllig, Christoph"' showing total 970 results

Search Constraints

Start Over You searched for: Author "Röllig, Christoph" Remove constraint Author: "Röllig, Christoph"
Sorry, I don't understand your search. ×
970 results on '"Röllig, Christoph"'

Search Results

2. How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned

3. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

4. Prognostic impact of CEBPA mutational subgroups in adult AML

5. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia

6. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

7. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

9. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience

10. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

11. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

12. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

13. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

14. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

15. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

16. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)

17. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

18. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

19. Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs

20. Overlapping features of therapy-related and de novo NPM1-mutated AML

23. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

24. Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study

25. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

26. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

27. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

28. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

29. Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse

31. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

34. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

35. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

36. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

37. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

38. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

39. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

40. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

41. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens

42. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

43. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

45. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

46. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

47. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

50. How to customize Common Data Models for rare diseases: an OMOP-based implementation and lessons learned

Catalog

Books, media, physical & digital resources